<DOC>
	<DOC>NCT03023423</DOC>
	<brief_summary>The purpose of the study is to compare the overall response rate (ORR) in non-small cell lung cancer (NSCLC) participants treated with daratumumab in combination with atezolizumab versus atezolizumab alone.</brief_summary>
	<brief_title>A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Have histologically or cytologically confirmed advanced or metastatic nonsmall cell lung cancer (NSCLC) (Stage IIIb or IV) Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 response criteria Known programmed deathligand 1 (PDL1) tumor status as determined by an immunohistochemistry (IHC) assay performed by the central laboratory on tissue obtained at Screening A woman of childbearing potential must have a negative highly sensitive serum (betahuman chorionic gonadotropin [beta hCG]) at Screening within 14 days prior to study drug administration Received any of the following prescribed medications or therapies in the past: 1. Anticluster of differentiation(CD)38 therapy, including daratumumab 2. CD137 agonists, immune checkpoint inhibitors including but not limited to anticytotoxicTlymphocyteassociated antigen 4 (CTLA4), antiPD1, and antiPDL1 therapies Known to be seropositive for human immunodeficiency virus (HIV) Prior allogeneic bone marrow transplantation or solid organ transplant History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins Active hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg] or antibodies to hepatitis B surface and core antigens [antiHBs and antiHBc, respectively]) or hepatitis C (anti HCV antibody positive or HCVRibonucleic acid [RNA] quantitation positive)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>